SOLVD Health Expands Patient Access with New Lab Approval
SOLVD Health, a pioneering patient intelligence company, has garnered noteworthy approval from the New York State Department of Health for its laboratory located in San Diego. This significant milestone allows SOLVD Health to provide its AvertD® genetic test to patients across New York. The innovative test is a crucial tool in the ongoing fight against opioid use disorder (OUD), empowering healthcare providers to gain essential insights for enhancing patient health outcomes.
Key Insights into the AvertD® Test
The AvertD® genetic test, which has already received FDA approval, plays a vital role in identifying individual genetic susceptibilities associated with developing OUD. This genetic assessment helps tailor personalized pain management strategies for patients, potentially guiding them toward safer, more effective treatment options.
The Importance of State Approval
The New York State Department of Health is renowned for its stringent standards. By meeting these rigorous benchmarks, SOLVD Health underscores its commitment to patient safety and the reliability of its testing methods. With this approval, SOLVD aims to make a positive impact on the lives of many individuals at risk of opioid addiction.
Quotes from Leadership
Dr. Keri Donaldson, the founder and CEO of SOLVD Health, expressed enthusiasm about this achievement: "Securing New York State approval is a pivotal step in our mission to expand access to genetic testing that can help address the opioid crisis. This expansion enables more healthcare providers and patients to benefit from personalized health insights that can inform decisions about pain management and potentially prevent adverse outcomes."
Contributing to the Opioid Crisis Solution
Amidst the increasing urgency for innovative solutions to combat the opioid epidemic, SOLVD Health's AvertD® test is at the forefront of the solution. The approval reinforces the company's mission to transform complex biological signals into practical, actionable patient data, enabling providers and patients to make informed health decisions.
About SOLVD Health
SOLVD Health is dedicated to revolutionizing healthcare by ensuring that contextual health information is accessible to all. The company focuses on preventing disease by transforming intricate biological data into straightforward, actionable insights for both individuals and their healthcare providers. By doing so, SOLVD empowers families to make informed health choices and pursue better wellness outcomes. For more information about SOLVD Health and its career opportunities, visit their official website.
Frequently Asked Questions
What is the significance of SOLVD Health's lab approval?
The approval allows SOLVD Health to offer its AvertD® genetic test in New York, aiding in the early identification of opioid use disorder risk.
What does the AvertD® genetic test assess?
The AvertD® test evaluates individual genetic predispositions that may increase susceptibility to opioid use disorder.
How does SOLVD Health contribute to combating the opioid crisis?
SOLVD Health provides actionable insights through its genetic testing, supporting personalized pain management strategies to prevent opioid dependency.
Who is leading SOLVD Health?
The company is founded and led by Dr. Keri Donaldson, who emphasizes the importance of genetic testing in addressing healthcare challenges.
What is SOLVD Health's primary mission?
SOLVD Health aims to make health information accessible and actionable, enabling better health decisions and improving outcomes for individuals and families.
